PMID- 10526701
OWN - NLM
STAT- MEDLINE
DCOM- 19991116
LR  - 20131121
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - 22 Suppl 5
DP  - 1999 Oct
TI  - The mortality effect of metoprolol CR/XL in patients with heart failure: results 
      of the MERIT-HF Trial.
PG  - V30-5
AB  - The study was undertaken to investigate the effect of metoprolol CR/XL on 
      all-cause mortality in patients with heart failure in New York Heart Association 
      (NYHA) class II-IV. In all, 3,991 patients in NYHA class II-IV who were stable on 
      standard medical treatment, including angiotensin-converting enzyme inhibitors, 
      diuretics, and digitalis, were randomized to metoprolol CR/XL or placebo and 
      uptitrated from 12.5 or 25 mg to 200 mg over an 8-week period and were planned to 
      be followed for a period of 2 years. The study was stopped earlier than planned 
      due to the significant benefit achieved with metoprolol CR/XL on all-cause 
      mortality. Treatment with metoprolol CR/XL was associated with a 34% decrease in 
      all-cause mortality, 38% decrease in cardiovascular mortality, 41% decrease in 
      sudden death, and 49% decrease in death due to progressive heart failure. The 
      average dose of metoprolol CR/XL at the end of the study was 159 mg, and 64% of 
      the patients were receiving 200 mg of metoprolol CR/XL. There was no significant 
      difference in the placebo and active treatment group with regard to permanent 
      discontinuation. Treatment of patients in NYHA class II-IV with metoprolol CR/XL 
      is associated with a significant decrease in total mortality.
FAU - Goldstein, S
AU  - Goldstein S
AD  - Henry Ford Heart Vascular Institute, Detroit, Michigan 48202, USA.
FAU - Hjalmarson, A
AU  - Hjalmarson A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Delayed-Action Preparations)
RN  - GEB06NHM23 (Metoprolol)
SB  - IM
MH  - Adrenergic beta-Antagonists/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Delayed-Action Preparations
MH  - Female
MH  - Heart Failure/*drug therapy/*mortality
MH  - Humans
MH  - Male
MH  - Metoprolol/*therapeutic use
MH  - Middle Aged
MH  - Prognosis
MH  - Survival Analysis
MH  - Survival Rate
MH  - Sweden/epidemiology
MH  - Treatment Outcome
EDAT- 1999/10/20 00:00
MHDA- 1999/10/20 00:01
CRDT- 1999/10/20 00:00
PHST- 1999/10/20 00:00 [pubmed]
PHST- 1999/10/20 00:01 [medline]
PHST- 1999/10/20 00:00 [entrez]
PST - ppublish
SO  - Clin Cardiol. 1999 Oct;22 Suppl 5:V30-5.